ArticleFrontiers in oncology2026
Integration of multiparametric MRI and clinical indicators to predict response to immune-targeted therapy in patients with advanced hepatocellular carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this investigation is to evaluate the efficacy of a predictive model integrating multiparametric MRI and clinical indicators for forecasting the therapeutic response to immune-targeted therapy in patients with advanced hepatocellular carcinoma (HCC). Methods: This retrospective analysis included 78 patients with HCC who received immune-targeted therapy between January 2021 and October 2024. Abdominal MRI scans were conducted within 2 weeks prior to treatment initiation and again at 8 weeks post-treatment. Complete pre-treatment laboratory data were available for all patients. Based on the Modified Response Evaluation Criteria in Solid Tumors (mRECIST), the patients were categorized into either a disease control group ( Results: Independent predictors for response to therapy in advanced HCC included the post-treatment T2 signal intensity ratio (T2 SIR) ( Conclusion: The MRI-clinical nomogram provided effective discrimination of treatment responses to immune-targeted therapy in advanced HCC, thereby enhancing predictive efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.